{
  "event": {
    "ticker": "CYTK",
    "company": "Cytokinetics, Incorporated",
    "drug": "aficamten (MYQORZO; CK-3773274)",
    "application_type": "sNDA",
    "indication": "Efficacy supplement to NDA 219083 (MYQORZO, approved 2025-12-19 for adults with symptomatic obstructive HCM) to add the MAPLE-HCM results (aficamten monotherapy vs metoprolol monotherapy) to the label",
    "pdufa_date": "2026-11-14"
  },
  "display": {
    "company": "Cytokinetics",
    "drug": "aficamten",
    "indication_en": "Obstructive HCM",
    "indication_zh": "梗阻性肥厚型心肌病"
  },
  "probability_approval": 0.96,
  "confidence": "high",
  "base_rate_used": 0.95,
  "key_factors": [
    {
      "factor": "The supporting trial is clearly positive",
      "direction": "+",
      "step": "small",
      "evidence": "MAPLE-HCM (n=175, double-blind, double-dummy) found aficamten monotherapy better than metoprolol monotherapy on change in peak VO2 at week 24: +1.1 vs -1.2 mL/kg/min, difference 2.3 (95% CI 1.5 to 3.1), p<0.001. NYHA class, KCCQ-CSS, LVOT gradient, NT-proBNP and left atrial volume index were also significantly better. Published in NEJM.",
      "source": "Garcia-Pavia et al., N Engl J Med 2025;393:949-960 (doi:10.1056/NEJMoa2504654); Cytokinetics 10-Q filed 2026-08-06"
    },
    {
      "factor": "No new safety or risk-management question for the reviewers",
      "direction": "+",
      "step": "small",
      "evidence": "Adverse events looked similar in the aficamten and metoprolol arms. The drug already has a boxed warning for heart failure from systolic dysfunction and an echo-monitoring REMS (REMS supplement S-001 approved 2026-02-05). The supplement adds trial data to an existing indication rather than a new population.",
      "source": "NEJM MAPLE-HCM; openFDA Drugs@FDA NDA219083; Cytokinetics 10-Q filed 2026-08-06"
    },
    {
      "factor": "The review division approved the original NDA in its first cycle, and nothing negative has been disclosed on this supplement",
      "direction": "+",
      "step": "small",
      "evidence": "The original NDA was approved 2025-12-19 after a 3-month extension, which came because FDA asked mid-review for a REMS. FDA requested no new clinical data. The sNDA was submitted January 2026 and accepted with standard review and a PDUFA date of November 14, 2026. The August 2026 10-Q and the Q2 release report no extension, advisory committee or new FDA requests.",
      "source": "Cytokinetics 8-K (Q1 2025 release) and Medthority on the 2025 extension; 8-K 2026-05-05; 10-Q filed 2026-08-06"
    },
    {
      "factor": "Possible disagreement over comparative-efficacy wording against metoprolol",
      "direction": "-",
      "step": "small",
      "evidence": "Metoprolol is used off-label in HCM, and FDA is generally cautious about head-to-head superiority claims in labeling. If there is a disagreement, it would more likely narrow the Clinical Studies text than lead to a CRL. A narrower label still counts as approval.",
      "source": "Analyst judgment; no public FDA statement on this sNDA"
    }
  ],
  "manufacturing_risk": {
    "level": "low",
    "why": "The drug is a small-molecule tablet that has been made and sold commercially since January 2026 (US, EU and China approvals). The supplement is clinical/labeling only, so no new facility or process needs approval."
  },
  "what_would_change_my_mind": [
    "Disclosure of a PDUFA extension or of FDA requests for more analyses (an extension would mostly move the date)",
    "A new postmarketing safety signal, such as heart-failure events coming through REMS or FOREST-HCM data, that changes how FDA views monotherapy use",
    "Any company statement about label negotiations narrowing or dropping the MAPLE-HCM claims"
  ],
  "summary_en": "We put approval at 96%. This is a supplement to MYQORZO (aficamten), approved for obstructive HCM in December 2025, that asks FDA to add the MAPLE-HCM results to the label. MAPLE-HCM was clearly positive: aficamten monotherapy beat metoprolol on peak VO2 by 2.3 mL/kg/min (p<0.001), all key secondary endpoints were significant, and adverse events were similar (NEJM 2025). The drug, its REMS and its manufacturing are already approved, so the review raises few new questions. The main remaining risk is disagreement over comparative wording against metoprolol, which would more likely narrow the label than block approval. Confidence is high.",
  "summary_zh": "我们估计获批概率为96%。这是一份补充申请（sNDA）：MYQORZO（aficamten）已于2025年12月获批用于梗阻性肥厚型心肌病，本次申请把MAPLE-HCM试验结果写入说明书。该试验结果明确：aficamten单药在峰值摄氧量上比美托洛尔多改善2.3 mL/kg/min（p<0.001），关键次要终点均显著，不良事件相近。药物、REMS和生产均已获批，审评中的新问题很少。主要剩余风险是FDA可能不认可与美托洛尔比较的措辞，但更可能只是收窄说明书文字，而非拒绝批准。把握度高。",
  "sources": [
    "https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm (10-Q filed 2026-08-06: sNDA submitted Jan 2026, standard review, PDUFA 2026-11-14; REMS)",
    "https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-ex99_1.htm (8-K 2026-05-05, Q1 2026 release: sNDA accepted, PDUFA 2026-11-14)",
    "https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/cytk-ex99_1.htm (8-K 2026-02-24, Q4 2025 release: sNDA submitted)",
    "https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-ex99_1.htm (8-K 2026-08-06, Q2 2026 release)",
    "https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/cytk-ex99_1.htm (8-K 2026-08-28: ACACIA-HCM; separate nHCM sNDA planned for Q4 2026)",
    "https://doi.org/10.1056/NEJMoa2504654 (MAPLE-HCM, NEJM 2025; PubMed 40888697)",
    "https://api.fda.gov/drug/drugsfda.json?search=application_number:NDA219083 (Drugs@FDA: ORIG approved 2025-12-19; S-001 REMS approved 2026-02-05)",
    "https://www.sec.gov/Archives/edgar/data/1061983/000095017025064432/cytk-ex99_1.htm (2025 release: REMS-driven 3-month extension of the original NDA)",
    "https://www.medthority.com/news/2025/5/new-pdufa-date-for-aficamten-in-obstructive-hypertrophic-cardiomyopathy---cytokinetics/",
    "https://www.hcplive.com/view/fda-approves-aficamten-myqorzo-for-symptomatic-obstructive-hypertrophic-cardiomyopathy (approval with boxed warning and REMS)"
  ],
  "zh": {
    "indication": "针对新药申请（NDA）219083（MYQORZO，2025 年 12 月 19 日获批用于有症状的梗阻性肥厚型心肌病（HCM）成人患者）的疗效补充申请，拟将 MAPLE-HCM 研究结果（aficamten 单药对比 metoprolol 单药）纳入说明书",
    "key_factors": [
      {
        "factor": "支持性试验结果明确为阳性",
        "evidence": "MAPLE-HCM（n=175，双盲、双模拟）显示，在第 24 周峰值摄氧量（peak VO2）变化方面，aficamten 单药优于 metoprolol 单药：+1.1 对 -1.2 mL/kg/min，差值 2.3（95% CI 1.5 至 3.1），p<0.001。NYHA 心功能分级、KCCQ-CSS、左心室流出道（LVOT）压差、NT-proBNP 和左心房容积指数亦显著改善。研究结果已发表于 NEJM。"
      },
      {
        "factor": "审评人员不会面临新的安全性或风险管理问题",
        "evidence": "aficamten 组和 metoprolol 组的不良事件情况相似。该药已带有收缩功能障碍所致心力衰竭的黑框警告，以及要求超声心动图监测的风险评估与减低策略（REMS；REMS 补充申请 S-001 已于 2026 年 2 月 5 日获批）。本补充申请是在现有适应症中增加试验数据，而非扩展到新的人群。"
      },
      {
        "factor": "审评部门在首轮审评中即批准了原 NDA，本补充申请也未披露任何负面信息",
        "evidence": "原 NDA 于 2025 年 12 月 19 日获批，此前经历了 3 个月延期，起因是 FDA 在审评中途要求制定 REMS。FDA 未要求新的临床数据。补充申请（sNDA）于 2026 年 1 月提交，获受理并适用标准审评，PDUFA 目标日期为 2026 年 11 月 14 日。2026 年 8 月的 10-Q 和第二季度业绩公告均未报告延期、专家咨询委员会会议或 FDA 的新要求。"
      },
      {
        "factor": "在相对 metoprolol 的疗效比较表述上可能存在分歧",
        "evidence": "Metoprolol 在 HCM 中属于超说明书使用，且 FDA 通常对说明书中的头对头优效性声明持谨慎态度。即便出现分歧，更可能的结果是“临床研究”部分的表述收窄，而非完全回应函（CRL）。说明书范围收窄仍计为获批。"
      }
    ],
    "manufacturing_risk_why": "该药为小分子片剂，自 2026 年 1 月起已实现商业化生产和销售（已在美国、欧盟和中国获批）。本补充申请仅涉及临床/说明书内容，无需批准新的生产设施或工艺。",
    "what_would_change_my_mind": [
      "披露 PDUFA 目标日期延期或 FDA 要求补充分析（延期主要只会推迟日期）",
      "出现新的上市后安全性信号，例如通过 REMS 或 FOREST-HCM 数据发现的心力衰竭事件，从而改变 FDA 对单药使用的看法",
      "公司任何有关说明书谈判中 MAPLE-HCM 相关声明被收窄或删除的表态"
    ]
  },
  "recorded_at": "2026-10-04T19:58:07+00:00"
}